MX2021011335A - Antagonistas de ngf para uso medicinal. - Google Patents

Antagonistas de ngf para uso medicinal.

Info

Publication number
MX2021011335A
MX2021011335A MX2021011335A MX2021011335A MX2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A
Authority
MX
Mexico
Prior art keywords
ngf
medical use
ngf antagonists
polypeptides
trka
Prior art date
Application number
MX2021011335A
Other languages
English (en)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Fawn Qian
Richard Chin
Qingyi Chu
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2021011335A publication Critical patent/MX2021011335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan varias modalidades relacionadas con los polipéptidos TrkA ECD de las especies de animales de compañía que se unen a NGF; tales polipéptidos pueden usarse en métodos para tratar condiciones inducidas por NGF relacionadas con dolor crónico y/o dolor inflamatorio en animales de compañía, tales como caninos, felinos y equinos.
MX2021011335A 2019-03-20 2020-03-20 Antagonistas de ngf para uso medicinal. MX2021011335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821438P 2019-03-20 2019-03-20
PCT/US2020/023846 WO2020191289A1 (en) 2019-03-20 2020-03-20 Ngf antagonists for medical use

Publications (1)

Publication Number Publication Date
MX2021011335A true MX2021011335A (es) 2022-01-06

Family

ID=72521232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011335A MX2021011335A (es) 2019-03-20 2020-03-20 Antagonistas de ngf para uso medicinal.

Country Status (10)

Country Link
US (1) US20220169740A1 (es)
EP (1) EP3941933A4 (es)
JP (1) JP2022525754A (es)
KR (1) KR20220066002A (es)
CN (1) CN113840831A (es)
AU (1) AU2020240120A1 (es)
BR (1) BR112021018156A2 (es)
CA (1) CA3133104A1 (es)
MX (1) MX2021011335A (es)
WO (1) WO2020191289A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453716A (zh) * 2018-12-27 2021-09-28 金德雷德生物科学股份有限公司 兽用IgG Fc变体
MX2022012866A (es) * 2020-04-17 2022-11-08 Zoetis Services Llc Variantes de anticuerpos caninos.
EP4388004A1 (en) 2021-08-20 2024-06-26 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
AU2022369106A1 (en) * 2021-10-21 2024-04-11 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
WO2007059574A1 (en) * 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US7342146B2 (en) * 2006-01-11 2008-03-11 Industrial Technology Research Institute Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
CN111182915A (zh) * 2017-08-15 2020-05-19 金德雷德生物科学股份有限公司 兽药用IgG Fc变体
CN113453716A (zh) * 2018-12-27 2021-09-28 金德雷德生物科学股份有限公司 兽用IgG Fc变体

Also Published As

Publication number Publication date
EP3941933A1 (en) 2022-01-26
KR20220066002A (ko) 2022-05-23
CA3133104A1 (en) 2020-09-24
EP3941933A4 (en) 2023-07-26
JP2022525754A (ja) 2022-05-19
BR112021018156A2 (pt) 2021-11-16
US20220169740A1 (en) 2022-06-02
AU2020240120A1 (en) 2021-09-30
WO2020191289A1 (en) 2020-09-24
CN113840831A (zh) 2021-12-24

Similar Documents

Publication Publication Date Title
MX2021011335A (es) Antagonistas de ngf para uso medicinal.
MX2019012570A (es) Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.
MX2022013192A (es) Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
MX2021004313A (es) Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
MX2019014875A (es) Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
EA201992757A1 (ru) Биспецифические антитела-ингибиторы контрольной точки
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
EA201190273A1 (ru) Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз
EA201790213A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
CY1123007T1 (el) Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2016002719A (es) Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
CY1111796T1 (el) Ανοσοθεραπευτικο cd37 και συνδυασμος αυτου με διλειτουργικο χημειοθεραπευτικο
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
BR112012026718A2 (pt) antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.
BR112018016329A2 (pt) 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
BR112015031719A2 (pt) método para preparar aditivo de ração
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
MY174691A (en) Il-18 binding molecules
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2016010953A (es) Proteinas de fc multimericas.
MX2020006508A (es) Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
BR112018009361A2 (pt) composições e métodos para o tratamento de doenças autoimunes e de câncer